CADRENAL THERAPEUTICS INC (CVKD:NASDAQ)

$1.57 -0.04 (-2.4845%)

watchlist-icon
search-icon
Profile Icon

Most Recent Average Sentiment Analysis Score (0 to 100): 84

negative-sentiment
Negative [0, 35)
neutral-sentiment
Neutral [35, 65]
positive-sentiment
Positive (65, 100]
Visualize Sentiment Trendline

Analysed CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) News Sources

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

07-05-2026

yahoo.com

CVKD: Designing Phase 3 Trial for CAD-1005 in HIT

08-05-2026

yahoo.com

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

19-05-2026

yahoo.com

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

03-06-2026

yahoo.com

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

24-06-2026

yahoo.com

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

01-07-2026

yahoo.com

Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

13-07-2026

yahoo.com

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

21-07-2026

yahoo.com

CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy

03-08-2026

yahoo.com

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

13-08-2026

yahoo.com

CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) Sentiment Trend

0 25 50 75 100 80 82 77 86 87 83 79 89 91 88 07-05-2026 08-05-2026 19-05-2026 03-06-2026 24-06-2026 01-07-2026 13-07-2026 21-07-2026 03-08-2026 13-08-2026 #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Negative < 35 Neutral 35–65 Positive > 65 View FAQ

CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) FAQs

toggle

What is the current price of CADRENAL THERAPEUTICS INC (CVKD:NASDAQ)?

The current price of CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) is $1.57.


toggle

CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) absolute price change since previous trading day?

The absolute price change of CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) since the previous trading day is $-0.04.


toggle

CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) percentage price change since previous trading day?

The percentage price change of CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) since the previous trading day is -2.4845%.


toggle

What is the most recent average sentiment score for CADRENAL THERAPEUTICS INC (CVKD:NASDAQ)?

The most recent average sentiment score for CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) is 84 out of 100.


toggle

What is the most recent average sentiment for CADRENAL THERAPEUTICS INC (CVKD:NASDAQ)?

The most recent sentiment for CADRENAL THERAPEUTICS INC (CVKD:NASDAQ) is .


SEC-8K** Filing Available For CADRENAL THERAPEUTICS INC (CVKD:NASDAQ)

** material developments that could impact a company's financial condition or stock price.

Author: MattELab

X Icon

GitHub Icon

MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.